May 2026
📣 VC round data is live. Check it out!
Largest HealthTech Public Companies in France
Benchmark revenue and EBITDA valuation multiples for public comps like
bioMérieux, Nanobiotix, Ramsay Santé, Equasens and SOPHiA Genetics.
 | BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France. | $85 | -37% | $10B | $10B | 2.1x | 8.4x | ||
| Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies. | $42 | +900% | $2B | $2B | 55.5x | (150.0x) | ||
| Ramsay Generale de Sante SA operates in the private healthcare sector in France. The company provides a comprehensive range of patient care services in thirteen business segments: Nouvelle Aquitaine, Bourgogne-Franche Comte, Brittany, Centre-Val de Loire, Hauts de France, Normandy, Provence Alpes Cote d'Azur, Ile de France, Auvergne-Rhone Alpes, Occitanie, Italy, Nordics, and Head Office. It generates maximum revenue from the Ile de France segment. The company also specializes in cardiology, heart surgery, digestive surgery, dermatology, urology, ophthalmology, vascular and endovascular surgery. | $12 | -1% | $1B | $6B | 0.9x | 8.4x | ||
| Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available. | $44 | -24% | $657M | $626M | 2.3x | 7.6x | ||
| Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil. | $5 | +63% | $352M | $349M | 4.5x | (8.4x) | ||
| Eurobio Scientific is one of the leading providers of specialty in vitro diagnostics and life-science solutions. The product portfolio includes Tetanos Quick Stick, BJI InoPlex, AlloMap, and TEDAC Consortium. | $26 | -11% | $260M | $254M | 1.3x | 7.8x | ||
| Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The company focuses on the oncology clinical trials market and the cancer patient care market. The company has two platforms, iSee for imaging services in clinical trials and eyonis for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer. Its revenue is generated from contracts for providing imaging services for oncology clinical trials using dedicated software. Geographically, the company generates revenue from EMEA, the USA/Canada, and China. | $6 | +147% | $239M | $243M | 8.9x | (13.1x) | ||
| Carvolix SA specializes in the development of AI-based mini-robots and biomimetic implants designed to autonomously replace heart valves and treat strokes. | $4 | +117% | $213M | $234M | 48.8x | (16.8x) | ||
| IEVA Group SA specializes in the development and marketing of skincare and beauty products (face and body care, makeup, hair care, etc.). In addition, the group designs and develops skin and hair diagnostic tools, artificial intelligence-based applications, and connected devices that analyze skin and hair condition and environmental impact, and offer personalized beauty routines. IEVA Group has organized its activities into three operational Business Units - IEVA Tech, IEVA Beauty, and IEVA Experience. | $9 | -- | $92M | $85M | 1.7x | (250.2x) | ||
| SMAIO SA is engaged in offering spine surgeons a complete solution, consisting of software, implantable devices, and associated services, to treat spinal pathologies requiring surgery. | $9 | +112% | $58M | $57M | 5.3x | (55.3x) | ||
| Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment. | $1 | +2% | $49M | $37M | 1.4x | (3.5x) | ||
| Theraclion is a France-based company specializing in high-tech therapeutic ultrasound equipment. The product, Echopulse, helps in the treatment of breast fibroadenomas and benign thyroid nodules. | $1 | +74% | $41M | $42M | 43.9x | (6.2x) | ||
| Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company’s flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia with the majority of the revenue deriving from USA and Canada. | $0 | +102% | $40M | $48M | 5.0x | 3.2x | ||
| Diagnostic Medical Systems is France's company engaged in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group’s activity is organized around two sectors: Radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; and the Development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. | $1 | +7% | $38M | $50M | 0.9x | 9.3x | ||
| Implanet SA designs produce and sell medical implants and devices used in orthopedic surgery. Its products include prosthetic knees, spinal bracing systems, intersomatic cages, pins, suture threads, screws, and anchors. The company operates in a single segment - the commercialization of orthopedic implants. It derives Majority of its geographical revenue from France. | $0 | +98% | $32M | $35M | 2.4x | (8.1x) | ||
| Biosynex SA is engaged in the research, development, and manufacturing of fast diagnosis tests on membrane support for health professionals. It manufactures and markets medical devices for screening, diagnosis. | $1 | -20% | $22M | $84M | 0.8x | 60.4x | ||
| Obiz SA is specialized in the design, development and animation of relationship marketing programs. The company offers benefit programs on personalized responsive web platforms, data collection and analysis solutions to improve customer knowledge and targeting, consulting and support services. | $3 | -37% | $17M | $39M | 0.3x | (38.6x) | ||
| Spineguard is engaged in the design and production of medical instruments used for spinal surgeries. It is deploying its proprietary radiation-free real time sensing technology DSG (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. It designs, develops and markets medical devices embedding its technology. | $0 | +0% | $11M | $10M | 2.3x | (8.0x) | ||
| Bluelinea SA is engaged in designing and developing of electronic surveillance and medical teleassistance systems. | $0 | -42% | $9M | $12M | 0.9x | 15.4x | ||
| Carmat is a France-based company dedicated to designing, manufacturing, and marketing Aeson, the artificial heart. The company's mission is to establish Aeson as the primary alternative to heart transplantation, offering a life-saving therapeutic option for patients with end-stage biventricular heart failure who face a severe shortage of donor hearts. | $0 | -88% | $7M | $72M | — | — | ||
| AMA Corp PLC specializes in the development of remote assistance, inspection, and training solutions involving connected glasses, a dedicated smartphone, and external video sources such as webcams, thermographic cameras, endoscopes, microscopes, and others. Geographically the company operates in Europe, which includes subsidiaries in France, Germany, the UK, Romania, Italy and Spain and which invoice customers in Europe; North America, which includes subsidiaries in the United States and Canada and which invoice customers in the North American area; and lastly Asia, which includes subsidiaries in Hong Kong, Shanghai and Japan and which invoice customers in the Asia area. | $0 | -51% | $7M | $8M | 3.5x | (1.4x) | ||
| Median | $3 | +1% | $49M | $72M | 2.3x | (4.9x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.